Reaction
Hypertensive Cardiomyopathy reporting signals
As of the last recalculation, Hypertensive Cardiomyopathy appears in 279 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is CANAKINUMAB (PRR 140.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Canakinumab | 19 | 140.5 | 140.8 |
| Tofacitinib Citrate | 20 | 122.5 | 122.7 |
| Anakinra | 19 | 91.6 | 91.7 |
| Obinutuzumab | 15 | 71.8 | 71.9 |
| Bendamustine Hcl | 9 | 44.7 | 44.7 |
| Paricalcitol | 8 | 43.5 | 43.5 |
| Bendamustine Hydrochloride | 6 | 38.2 | 38.2 |